Skip to main content

Featured

Mass Displacement in Lebanon After Intensified Israeli Evacuation Warnings

                                                     Displaced people walk outside a school-turned-shelter, in Beirut Tens of thousands of Lebanese civilians have been forced into shelters after what officials described as “unprecedented” evacuation warnings issued by the Israeli military. Local authorities estimate that around 100,000 people have fled their homes in southern Lebanon within a short period, seeking safety in schools, public buildings, and makeshift community centers. The warnings follow a sharp escalation in cross‑border hostilities, with Israeli forces expanding the areas they instructed residents to evacuate. Lebanese municipalities and humanitarian groups say the pace and scale of displacement have overwhelmed available shelter capacity, leaving many families without adequate access to food, medical care, or basi...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment